SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate earnings, with the community debating whether strong results are already priced in or if the stock will skyrocket. Discussions include valuation concerns, potential for a stock split, and comparisons to other high-growth tech companies. Some traders are also pointing to possible catalysts beyond earnings, such as new government contracts and partnerships in the AI space.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss upcoming earnings and potential FDA-related news impacting its gene therapy, Elevidys. Community talking points revolve around revenue expectations, possible surprises in company guidance, and the potential for a short squeeze. Broader market sentiment and recent biotech sector activity are also influencing conversations around SRPT's valuation and future prospects.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences ($ENVB) is trending as traders discuss a potential short squeeze due to its low float and recent news, drawing comparisons to past squeezes like $BYND. Community members are actively speculating on potential price targets and anticipating a significant move, while also referencing a recent reverse stock split.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as community members discuss the potential for the stock to reach $900 and beyond, driven by optimism around FDA approval of their oral treatment and strong positioning in the weight loss market, while also generating concerns around pricing following Trump's comments. Community members are weighing the potential impact of competition from other pharma companies and strategic moves within the sector.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant FDA update regarding its Huntington's disease treatment, AMT-130, which has sparked volatility and a mix of reactions. The community is discussing the unexpected regulatory shift and its potential impact on the drug's approval timeline. Community members are also considering the possibility of a buyout, speculating on the stock's long-term potential and potential courses of action.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors eagerly await earnings and a potential Black Pearl deal announcement, with the community anticipating significant news. Discussions revolve around the company's shift towards AI infrastructure and its advantageous position in securing deals with major players, reflecting broader interest in AI-related stocks. Positive sentiment is fueled by comparisons to industry peers like IREN, which recently secured a major deal, boosting hopes for CIFR's growth potential.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending due to positive Phase 1 data for their leukemia drug TERN-701, leading to analyst upgrades and optimism about its potential to disrupt the CML treatment landscape; the community is discussing the implications of the data and potential future catalysts, with some speculating about a possible buyout. Despite a recent discontinuation of their GLP-1 program, TERN's stock is experiencing a surge, with investors focusing on the remaining oncology asset.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending downwards, prompting discussions about potential bottom levels and gap fills, as well as tariff implications. Community sentiment is mixed, with some investors expressing frustration while others see it as a buying opportunity. Despite recent earnings, the stock's performance is being weighed against broader market factors and concerns about future growth and consumer trends.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark is trending as investors digest the company's acquisition of Kenvue, with community discussions focusing on the deal's potential impact on KMB's stock value and dividend payouts. Some traders are considering short-term strategies around the CEO's appearance on Mad Money, while others are evaluating the long-term value and oversold conditions. Chatter also involves merger arbitrage strategies involving $KVUE.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending as the community discusses its potential as an AI-driven fintech platform following news of partnerships to expand its loan origination system. Bullish sentiment is fueled by comparisons to other high-growth tech companies, a relatively small float, and speculation around potential future price targets. Some investors are closely watching for potential short squeezes and upcoming earnings reports as possible catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kimberly-Clark to Buy Kenvue for $40B  Open Interest 11/03/2025

Get a jump start on the US trading day with Matt Miller and Dani Burger on 'Bloomberg Open Interest.' Deals Monday! Kimberly-Clark scoops up Tylenol maker Kenvue to create a consumer products giant...

Squawk Pod: Big Tech's big challenges & Transportation Sec. Sean Duffy - 11/03/25  Audio Only

Transportation Secretary Sean Duffy addresses the government shutdown's impact on travel and federal travel workers across the country as we enter the second month of the standstill in Washington...

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the...

Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their...

Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger

Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one...

Kimberly-Clark to buy Tylenol-maker for more than $40bn

The deal will unite two giants in the over-the-counter health business, bringing together brands like Kleenex and Benadryl...

Kimberly-Clark Corporation (KMB) said on Monday that it has entered into an agreement to purchase Tylenol manufacturer Kenvue (KVUE) in a deal valued at about $48.7 billion.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kimberly-clark-to-acquire-kenvue-creating-a-32-billion-global-health-and-wellness-leader-302602379.html">deal</a>, Kimberly-Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction. Kenvue shareholders will receive $3.50 per share in cash, as well as 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, for a total consideration of $21.01 per share to Kenvue shareholders. This represents a premium of about 46% from KVUE’s closing price on Friday and values Kenvue at an enterprise value of approximately $48.7 billion, Kimberly-Clark said.<h2 class="st-heading-2">Ownership Structure</h2>Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company, it added. Kimberly-Clark CEO Mike Hsu will be the chief executive of the combined company, and three members of the Kenvue Board will join the Kimberly-Clark board at the closing of the transaction.The transaction has been unanimously approved by the Board of Directors of both companies, Kimberley-Clark said. It is expected to close in the second half of 2026.According to Kimberly, Kenvue is uniquely positioned at the intersection of consumer packaged goods and healthcare, and the combination of the two companies can create a combined portfolio of complementary products. While Kimberly-Clark is known for Huggies diapers and Kleenex, Kenvue’s popular products include Band-Aid, Benadryl, Listerine, Neutrogena, and Tylenol.Notably, market expert Jim Cramer said on Monday that he sees the deal creating a “real rival” to Procter &amp; Gamble (PG).<stembedurl>https://x.com/jimcramer/status/1985312437810389345</stembedurl>Kenvue Chair Larry Merlo, meanwhile, said that the board is confident that the combination represents the "best path forward" for shareholders.Kimberly-Clark expects the combined company to generate approximately $32 billion in annual net revenues and approximately $7 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) based on current projections for 2025.KVUE shares rose 16% at the time of writing, while KMB stock fell 13%. &nbsp;<h2 class="st-heading-2">The Tylenol Issue</h2>The deal comes on the heels of <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-drops-after-texas-attorney-general-sues-company-alleging-deceptive-marketing-of-tylenol/cLGjSYkR3HD">turbulence</a> at Kenvue, including President Trump linking its popular painkiller Tylenol to autism. In late September, the President linked autism to childhood vaccine use and the use of Tylenol by women when pregnant. Though the claims are not backed by scientific evidence, it has created a divide in opinion on the popular drug. Kenvue has maintained that Tylenol is safe and its consumption is unrelated to autism.&nbsp; Kenvue was spun off from JNJ in 2023. In 2024, Kenvue’s net sales were $15.5 billion, of which Tylenol is estimated to account for about $1 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KVUE stayed within the ‘bullish’ territory while message volume stayed at ‘normal’ levels.KVUE stock is down by 22% this year and by about 28% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Shares Soar 16% After Inking $48.7B Deal With Kimberly-Clark

Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company. 

Equity

Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company. 


KMB Q3 Earnings Beat Estimates, Sales In Line With the Year-Ago Level

KMB's Q3 results highlight steady sales, solid volume gains and cost discipline amid ongoing margin pressures.


Kimberly-Clark (KMB) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Kimberly-Clark (KMB) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kimberly-Clark Announces Third Quarter 2025 Results, Updates 2025 Outlook

Kimberly-Clark Announces Third Quarter 2025 Results, Updates 2025 Outlook Kimberly-Clark Announces Third Quarter 2025 Results, Updates 2025 Outlook PR Newswire DALLAS, Oct. 30, 2025 Durable results...

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

KMB
Kimberly-Clark Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KMB News

KMBKimberly-Clark Corp.